Stockscreener 앱 받기
19.74
2.28%
-0.46
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Price-Driven Insight from (VRDN) for Rule-Based Strategy - Stock Traders Daily
Tangible book value per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Operating cash flow per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline - ad-hoc-news.de
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - AOL.com
Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances - AD HOC NEWS
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone - Yahoo Finance
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease - Sahm
VRDNViridian Therapeutics Inc Options - Finviz
If You Invested $1,000 in Viridian Therapeutics Inc (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike - Stock Titan
Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 options at $18.48 - Stock Titan
Fairmount-linked entities receive 32,341 Viridian (VRDN) stock options at $18.48 - Stock Titan
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know - The Globe and Mail
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-07-01 - Seeking Alpha
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30 - Moomoo
VRDN Maintained by Needham -- Price Target Raised to $34.00 - GuruFocus
FDA clears Viridian's veligrotug for TED as Lumvoa - Eyes On Eyecare
RBC Lifts Price Target on Viridian Therapeutics to $35 From $34, Keeps Outperform, Speculative Risk - Moomoo
VRDN Maintained by RBC Capital -- Price Target Raised to $35.00 - GuruFocus
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says - marketscreener.com
VRDN Maintained by Truist Securities -- Price Target Raised to $38 - GuruFocus
VRDN Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43 - Moomoo
Viridian Therapeutics | SCHEDULE 13G: Others - Moomoo
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval (NASDAQ:VRDN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE) - The Globe and Mail
Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED) - VisionMonday.com
Viridian launches first commercial product as US approves thyroid eye disease therapy - MSN
VRDN Upgraded by Wells Fargo -- Price Target Raised to $31 - GuruFocus
UBS reiterates Viridian Therapeutic stock rating on FDA approval By Investing.com - Investing.com Australia
Wedbush raises Viridian Therapeutic stock price target to $43 - Investing.com
Wedbush raises Viridian Therapeutic stock price target to $43 By Investing.com - Investing.com Canada
Viridian Therapeutic stock rating reiterated at Outperform by William Blair - Investing.com Canada
(VRDN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
New Viridian meridian? Hopes veli high in TED post-FDA win - BioWorld News
Wells Fargo Upgrades Viridian Therapeutics to Overweight From Equalweight - Moomoo
Viridian Therapeutics (VRDN) Receives Upgrade from Wells Fargo - GuruFocus
Wells Fargo Upgrades Viridian Therapeutics(VRDN.US) to Buy Rating, Raises Target Price to $31 - Moomoo
Citizens reiterates Viridian stock rating on FDA drug approval - Investing.com UK
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Benzinga
VRDN Reiterated by Needham -- Price Target Maintained at $32 - GuruFocus
Viridian Therapeutic stock gets FDA approval for thyroid eye disease drug - Investing.com Canada
Comcast, Viridian Therapeutics jump premarket; Doximity slips By Investing.com - Investing.com Canada
Viridian Therapeutics (VRDN) Soars 12% Following FDA Approval of Lumvoa - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595) - The Globe and Mail
Why is Viridian Therapeutics stock surging today? By Investing.com - Investing.com Canada
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday - Benzinga
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease - BioSpace
Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug - simplywall.st
VRDN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Viridian Therapeutics, Inc. – NASDAQ:VRDN - TradingView
FDA says yes to Viridian’s Lumvoa in TED - BioWorld News
2.64%
자본화:
|
볼륨(24시간):